Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An effective tumor-inhibiting siRNA delivery platform.

Biochemical and biophysical research communications·2026
Same author

Identification of siRNA silencing TGFβ1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma <i>in vivo</i>.

NAR cancer·2026
Same author

Systemic dual delivery of a tumor-inhibiting plasmid expressing p16 and shRaf.

Biochemical and biophysical research communications·2025
Same author

A Facile and Promising Delivery Platform for siRNA to Solid Tumors.

Molecules (Basel, Switzerland)·2024
Same author

pH modification of gel mobility shift improves polyplex selection In Vivo.

Biochemical and biophysical research communications·2024
Same author

Delivery of mRNA with Histidine-Lysine Peptides.

Methods in molecular biology (Clifton, N.J.)·2024

Related Experiment Video

Updated: Jun 16, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Advances in Systemic siRNA Delivery.

Qixin Leng1, Martin C Woodle, Patrick Y Lu

  • 1Department of Pathology, University of Maryland Baltimore, MSTF Building, 10 South Pine Street, Baltimore, MD 21201, USA.

Drugs of the Future
|February 18, 2010
PubMed
Summary

Small interfering RNA (siRNA) offers gene silencing but faces delivery challenges. This review explores synthetic non-viral carriers for effective siRNA therapeutics and in vivo systemic delivery.

More Related Videos

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

Related Experiment Videos

Last Updated: Jun 16, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Drug Delivery

Background:

  • Small interfering RNA (siRNA) enables sequence-specific gene silencing, revolutionizing research.
  • siRNA therapeutics show promise for various diseases but require intracellular delivery for efficacy.
  • The negative charge of siRNA poses a significant barrier to cellular uptake.

Purpose of the Study:

  • To review non-viral carrier strategies for siRNA delivery.
  • To focus on synthetic carriers for in vivo systemic siRNA delivery.
  • To highlight advancements in overcoming siRNA cellular membrane transport challenges.

Main Methods:

  • Review of current literature on non-viral siRNA delivery systems.
  • Analysis of various carrier types: liposomes, peptides, polymers, and aptamers.
  • Focus on carriers designed for in vivo systemic administration.

Main Results:

  • Numerous non-viral carriers are under investigation for siRNA therapeutics.
  • Promising carriers demonstrate low toxicity and enhanced specificity for disease targets.
  • Synthetic carriers are emerging as key solutions for in vivo delivery.

Conclusions:

  • Effective siRNA delivery is crucial for therapeutic success.
  • Non-viral carriers, particularly synthetic ones, are vital for overcoming delivery hurdles.
  • Advancements in carrier development pave the way for widespread clinical application of siRNA therapeutics.